gsk1278863 and Diabetic-Foot

gsk1278863 has been researched along with Diabetic-Foot* in 1 studies

Trials

1 trial(s) available for gsk1278863 and Diabetic-Foot

Article	Year
Randomized Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Topical Daprodustat in Healthy Volunteers and in Patients With Diabetic Foot Ulcers. Clinical pharmacology in drug development, 2019, Volume: 8, Issue:6 Daprodustat, a small-molecule inhibitor of prolyl hydroxylases, prevents breakdown of hypoxia-inducible factor (HIF), leading to increased transcription of HIF-responsive genes. This randomized, placebo-controlled study evaluated the safety, tolerability, and pharmacokinetics of a topical formulation of daprodustat in healthy volunteers (intact skin) and in patients with diabetic foot ulcers (DFUs) following single and/or 14-day repeat-dose administration. In the diabetic patients, exploratory assessments of wound area, volume, and depth were made to qualitatively assess effectiveness. Systemic absorption via topical application was limited across doses up to 1.0% at 100 mg/cm Topics: Administration, Topical; Adult; Aged; Barbiturates; Diabetic Foot; Drug Administration Schedule; Female; Glycine; Healthy Volunteers; Humans; Male; Middle Aged; Standard of Care	2019

Article

Year

Randomized Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Topical Daprodustat in Healthy Volunteers and in Patients With Diabetic Foot Ulcers.

Clinical pharmacology in drug development, 2019, Volume: 8, Issue:6

Daprodustat, a small-molecule inhibitor of prolyl hydroxylases, prevents breakdown of hypoxia-inducible factor (HIF), leading to increased transcription of HIF-responsive genes. This randomized, placebo-controlled study evaluated the safety, tolerability, and pharmacokinetics of a topical formulation of daprodustat in healthy volunteers (intact skin) and in patients with diabetic foot ulcers (DFUs) following single and/or 14-day repeat-dose administration. In the diabetic patients, exploratory assessments of wound area, volume, and depth were made to qualitatively assess effectiveness. Systemic absorption via topical application was limited across doses up to 1.0% at 100 mg/cm

Topics: Administration, Topical; Adult; Aged; Barbiturates; Diabetic Foot; Drug Administration Schedule; Female; Glycine; Healthy Volunteers; Humans; Male; Middle Aged; Standard of Care

2019